PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26663083-7	2016	Blocking autophagy by treating cells with 3-methyladenine or overexpressing dominant-negative ATG5 abolished the deficiency of the p38alpha MAPK-induced BACE1 protein reduction in cultured cells.	3-methyladenine	42-57	mitogen-activated protein kinase 14	Mus musculus	131-139	
33846234-6	2021	The ability of rosuvastatin to inhibit apoptosis and p38 phosphorylation was suppressed by treatment with 3-methyladenine (3-MA; an autophagy inhibitor) but promoted by rapamycin (an autophagy activator) treatment.	3-methyladenine	106-121	mitogen-activated protein kinase 14	Mus musculus	53-56	
33846234-6	2021	The ability of rosuvastatin to inhibit apoptosis and p38 phosphorylation was suppressed by treatment with 3-methyladenine (3-MA; an autophagy inhibitor) but promoted by rapamycin (an autophagy activator) treatment.	3-methyladenine	123-127	mitogen-activated protein kinase 14	Mus musculus	53-56	
24902807-9	2015	Importantly, pretreatment with 3-methyladenine (autophagy inhibitor) enhanced while rapamycin (autophagy inducer) decreased the expression of LOX-1, TLR4, and P-P38 MAPK.	3-methyladenine	31-46	mitogen-activated protein kinase 14	Mus musculus	161-169	
34137231-9	2021	After treatment with the autophagy inhibitor 3-MA, the expression levels of LC3, NFATc1, TRAF6, p-ERK, and p-p38 all decreased significantly (all 0.05).	3-methyladenine	45-49	mitogen-activated protein kinase 14	Mus musculus	109-112